Potassium clavulanate prices have declined sharply across India and China, driven by an aggressive supply-side push and weak seasonal demand. Factors include massive Chinese price cuts, India’s Production-Linked Incentive (PLI) scheme enhancing local capacity, and persistent oversupply. The global potassium clavulanate market, propelled by the need for advanced antibiotic therapies, faces both relief and challenge as input costs drop but profit margins compress, especially for Indian producers contending with Chinese competition.
Key Highlights
-
Potassium clavulanate bulk prices slid xxx in seven months, pressured by Chinese supplier discounts and Indian output ramp-up.
-
Retail demand remains subdued as inventories at U.S./European buyers are high, tempering restocking.
-
Indian API plants benefit from lower input costs and policy support, but face eroding margins against low-priced Chinese imports.
-
Improved logistics and energy softening further eased expenses, supporting aggressive supplier pricing.
Human health remains the dominant sector for potassium clavulanate, used chiefly in hospital and retail pharmacy settings for combination antibiotics. However, the typical Qx–Qx restocking peak did not materialize in the United States and Europe. Economically driven high inventories and cautious buying resulted in fewer new spot orders. Global retail sales of β-lactam/β-lactamase inhibitor combinations only modestly picked up, largely from emerging pharmaceutical markets. Demand for potassium clavulanate in India and Southeast Asia is driven by the increasing rate of antibiotic-resistant infection and higher awareness among healthcare...
